Chiesi Farmaceutici S.p.A. has acquired Cornerstone Therapeutics in a deal valued at approximately $107 million. Chiesi already owned 58% of Cornerstone’s outstanding shares and will acquire the remainder at $9.50 per share in cash. The move is intended to advance Chiesi’s initiative to build a larger global presence and will help strengthen its presence in the U.S. The acquisition creates a foundation for new projects in special care and respiratory disorders and will provide a sal...